Matthias Kroiß
A5042079657- Adrenal and Paraganglionic Tumors
- Cancer, Hypoxia, and Metabolism
- Hormonal Regulation and Hypertension
- Pituitary Gland Disorders and Treatments
- Glioma Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Adrenal Hormones and Disorders
- Neuroblastoma Research and Treatments
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Diet and metabolism studies
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- CAR-T cell therapy research
- Renal cell carcinoma treatment
- Metabolomics and Mass Spectrometry Studies
- Immunotherapy and Immune Responses
- RNA Research and Splicing
- Parathyroid Disorders and Treatments
- Hormonal and reproductive studies
- Lung Cancer Treatments and Mutations
- Ferroptosis and cancer prognosis
- Cancer-related Molecular Pathways
LMU Klinikum
2020-2025
Ludwig-Maximilians-Universität München
2020-2025
Universitätsklinikum Würzburg
2016-2025
Comprehensive Cancer Center Mainfranken
2016-2025
University of Würzburg
2016-2025
Ollscoil na Gaillimhe – University of Galway
2025
München Klinik
2020-2025
Metropolitan University
2023
DeepMind (United Kingdom)
2019
Helmholtz Zentrum München
2017
Adrenocortical carcinoma is a rare cancer that has poor response to cytotoxic treatment.We randomly assigned 304 patients with advanced adrenocortical receive mitotane plus either combination of etoposide (100 mg per square meter body-surface area on days 2 4), doxorubicin (40 day 1), and cisplatin 3 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g 1 5 in cycle 1; subsequent cycles) weeks. Patients disease progression received the alternative regimen as second-line therapy. The...
RET mutations occur in 70% of medullary thyroid cancers, and fusions rarely other cancers. In patients with RET-altered the efficacy safety selective inhibition are unknown.
Recurrence of adrenocortical carcinoma (ACC) even after complete (R0) resection occurs frequently. The aim this study was to identify markers with prognostic value for patients in clinical setting. From the German ACC registry, 319 European Network Study Adrenal Tumors stage I–III were identified. As an independent validation cohort, 250 from three countries included. Clinical, histological, and immunohistochemical correlated recurrence-free (RFS) overall survival (OS). Although univariable...
The indirect water-deprivation test is the current reference standard for diagnosis of diabetes insipidus. However, it technically cumbersome to administer, and results are often inaccurate. study compared with direct detection plasma copeptin, a precursor-derived surrogate arginine vasopressin.
Abstract The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the profiles and outcomes 1,310 patients (rare cancers, 75.5%) enrolled a prospective observational study by German Cancer Consortium that applies whole-genome/exome RNA sequencing to inform care adults with incurable cancers. On basis 472 single six composite biomarkers, cross-institutional tumor board provided evidence-based management recommendations, including diagnostic...
Cross-sectional imaging regularly results in incidental discovery of adrenal tumours, requiring exclusion adrenocortical carcinoma (ACC). However, differentiation is hampered by poor specificity characteristics. We aimed to validate a urine steroid metabolomics approach, using profiling as the diagnostic basis for ACC.
Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) despite extensive multimodal therapy. These tumors highly proliferative, frequently increased tumor mutational burden (TMB) compared carcinomas, elevated programmed death ligand 1 (PD-L1) levels. properties implicate responsiveness to antiangiogenic antiproliferative multikinase inhibitors such as lenvatinib, immune checkpoint pembrolizumab.
Adrenocortical carcinoma (ACC) is a rare malignancy that harbors dismal prognosis in advanced stages. Mitotane approved as an orphan drug for treatment of ACC and counteracts tumor growth steroid hormone production. Despite serious adverse effects, mitotane has been clinically used decades. Elucidation its unknown molecular mechanism action seems essential to develop better therapies. Here, we set out identify the target altered downstream mechanisms by combining expression genomics mass...
Treatment of refractory adrenocortical carcinoma (ACC) is not established. Animal experiments pointed toward adrenal toxicity sunitinib. The objective the study was to determine antitumor effects sunitinib in ACC. This a phase II, open-label trial using two-stage accrual design. conducted at two tertiary referral centers. Thirty-eight patients with ACC progressing after mitotane and one three cytotoxic chemotherapies participated study. intervention included standard dose (50 mg/d, 4 wk on,...
Surgery is the standard of care for localized adrenocortical carcinomas, but its role recurrent disease not well defined.Our objective was to evaluate clinical outcome after surgery recurrence.We conducted a retrospective analysis in 154 patients with first recurrence initial radical resection from German Adrenocortical Carcinoma Registry.We evaluated progression-free survival (PFS) and overall (OS) by Kaplan-Meier method identified prognostic factors Cox regression analysis.A total 101...
Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC). A correlation between mitotane patient outcome has not demonstrated an adjuvant setting.To compare recurrence-free (RFS) who reached maintained 1 4 vs did not.Retrospective analysis at six referral European centers.Patients ACC were radically resected 1995 2009 treated adjuvantly targeting of 14-20 mg/l.RFS (primary) overall...
Abstract Chromothripsis is a recently identified mutational phenomenon, by which presumably single catastrophic event generates extensive genomic rearrangements of one or few chromosome(s). Considered as an early in tumour development, this form genome instability plays prominent role onset. prevalence might have been underestimated when using low-resolution methods, and pan-cancer studies based on sequencing are rare. Here we analyse chromothripsis 28 types covering all major adult cancers...